The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and Alecensa have demonstrated significant survival improvements while the PD-1 / PD-L1 axis inhibitor Tecentriq in combination with chemotherapy has received regulatory approval for first-line metastatic nonsquamous NSCLC. In this dynamic scenario of rapidly evolving combinations of targeted and immunotherapy with chemotherapy, our primary research provides insight into the use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States
Primary Research: Survey of 101 medical oncologists in the United States
Key Drugs Covered: Keytruda, Opdivo, Tecentriq, Imfinzi, Tagrisso, Vizimpro, Avastin, Tarceva, Xalkori, Alecensa, Iressa, Gilotrif/ Giotrif